UNIGE document Scientific Article
previous document  unige:108522  next document
add to browser collection

Pharmacological Intervention to Modulate HDL: What Do We Target?

Woudberg, Nicholas J
Pedretti, Sarah
Lecour, Sandrine
Schulz, Rainer
Frias, Miguel A
Published in Frontiers in Pharmacology. 2017, vol. 8, p. 989
Abstract The cholesterol concentrations of low-density lipoprotein (LDL) and high-density lipoprotein (HDL) have traditionally served as risk factors for cardiovascular disease. As such, novel therapeutic interventions aiming to raise HDL cholesterol have been tested in the clinical setting. However, most trials led to a significant increase in HDL cholesterol with no improvement in cardiovascular events. The complexity of the HDL particle, which exerts multiple physiological functions and is comprised of a number of subclasses, has raised the question as to whether there should be more focus on HDL subclass and function rather than cholesterol quantity. We review current data regarding HDL subclasses and subclass-specific functionality and highlight how current lipid modifying drugs such as statins, cholesteryl ester transfer protein inhibitors, fibrates and niacin often increase cholesterol concentrations of specific HDL subclasses. In addition this review sets out arguments suggesting that the HDL3 subclass may provide better protective effects than HDL2.
PMID: 29403378
Full text
Article (Published version) (1.3 MB) - public document Free access
Research group Chimie et protéomique clinique (270)
(ISO format)
WOUDBERG, Nicholas J et al. Pharmacological Intervention to Modulate HDL: What Do We Target?. In: Frontiers in Pharmacology, 2017, vol. 8, p. 989. doi: 10.3389/fphar.2017.00989 https://archive-ouverte.unige.ch/unige:108522

202 hits



Deposited on : 2018-09-26

Export document
Format :
Citation style :